Abstract:William J. Barbaresi, MD In the 8 years since the publication of the study describing long-term stimulant medication treatment of attention-deficit hyperactivity disorder (ADHD) from early childhood through adolescence among children from a population-based birth cohort, there have been a number of studies that have added to our understanding and capacity to treat ADHD, the most common neurodevelopmental disorder in childhood.1–3 The original study demonstrated that nearly 80% of children with ADHD were treated with stimulant medication at some time during childhoodadolescence; treatment effectiveness was comparable with efficacy rates from previous clinical trials, and side effects occurred at an acceptable rate. However, treatment duration averaged just over 3 years. The imperative to ensure long-term treatment of ADHD has increased as studies, including additional reports from an adult follow-up of this cohort, have demonstrated the chronicity and adverse impact of ADHD from childhood through adulthood.4,5 Recent reports have demonstrated that ADHD is being diagnosed and treated at rates that continue to increase.3 Nevertheless, as in the original study, many children with ADHD continue to go untreated, and, perhaps most disturbing, the evidence continues to suggest that treatment is not continued into the highrisk adolescent and early adult years despite the known chronicity of ADHD and its attendant impact on adolescents and young adults.3,6 A number of new long-acting stimulant and nonstimulant medications have become available in recent years, and it is hoped that these treatment options, along with increased understanding about the chronicity of ADHD, will lead to improved rates of long-term treatment and improved outcomes (see http://www.webmd.com/addadhd/adhd-medication-chart for a list of currently available medications). UPDATES Rate of ADHD Diagnosis and Treatment in Childhood The issue of long-term treatment of ADHD can only be understood in the context of the epidemiology of the disorder, particularly given the high prevalence of ADHD because the US public continues to express concern about rates at which stimulant medications are prescribed to children. In a recent CDC report describing rates of parent-reported ADHD diagnosis among US children aged 4 to 17 years from 2003 to 2011, prevalence of having ever received an ADHD diagnosis increased from 7.8% to 11.0%.3 The reported 11.0% prevalence rate equates to 6.4 million children having received an ADHD diagnosis, whereas 8.0% (5.1 million) were reported to have a current ADHD diagnosis. However, among those with a current ADHD diagnosis, only 69.0% were taking ADHD medication (6.1% or 3.5 million children). This figure is somewhat lower than the 77.8% stimulant treatment rate in the 1976–1980 Rochester, MN birth cohort during childhood.1

Batch Preparation and Characterization of Anthocyanin/CS/PEO Nanofiber Membranes for Food Packages

Development and Characterization of Electrospun Nanofibers Based on Pullulan/chitin Nanofibers Containing Curcumin and Anthocyanins for Active-Intelligent Food Packaging.

Preparation of an intelligent film based on chitosan/oxidized chitin nanocrystals incorporating black rice bran anthocyanins for seafood spoilage monitoring.

In Situ Self-Assembly Chitosan/ε-Polylysine Bionanocomposite Film with Enhanced Antimicrobial Properties for Food Packaging.

Update on long-term stimulant medication treatment of attention-deficit hyperactivity disorder.

Mechanism of Action of Electrospun Chitosan-Based Nanofibers against Meat Spoilage and Pathogenic Bacteria

Electrospun nanofiber based on Ethyl cellulose/Soy protein isolated integrated with bitter orange peel extract for antimicrobial and antioxidant active food packaging

Albumin inhibits platelet‐activating factor (PAF)‐induced responses in platelets and macrophages: implications for the biologically active form of PAF

Antiulcer activity of pentacaine and some of its derivatives: effect on experimentally induced gastric and duodenal lesions and on gastric acid secretion in rats.

Electrospun essential oil-doped chitosan/poly(ε-caprolactone) hybrid nanofibrous mats for antimicrobial food biopackaging exploits

Application of Solution Blow Spinning to Rapidly Fabricate Natamycin-Loaded Gelatin/zein/polyurethane Antimicrobial Nanofibers for Food Packaging

Microfluidic-blow-spinning of carvacrol-loaded porphyrin metal - organic framework nanofiber films with synergistic antibacterial capabilities for food packaging

Electrospun gelatin/tea polyphenol@pullulan nanofibers for fast-dissolving antibacterial and antioxidant applications

EGCG/HP-β-CD inclusion complexes integrated into PCL/Chitosan oligosaccharide nanofiber membranes developed by ELS for fruit packaging

Rehabilitation methodology: international survey.

Novel Polyamide/Chitosan Nanofibers Containing Glucose Oxidase and Rosemary Extract: Fabrication and Antimicrobial Functionality

Preparation and characterization of catechol-grafted chitosan/gelatin/modified chitosan-AgNP blend films

A biodegradable bi‐layer nano fibrous membrane fabricated by centrifugal spinning for active food packaging

Development of a multifunctional active food packaging membrane based on electrospun polyvinyl alcohol/chitosan for preservation of fruits

Preparation of Amphiphilic Polyquaternium Nanofiber Films with Antibacterial Activity Via Environmentally Friendly Microfluidic-Blow-spinning for Green Food Packaging Applications.

Baicalin-liposomes loaded polyvinyl alcohol-chitosan electrospinning nanofibrous films: Characterization, antibacterial properties and preservation effects on mushrooms